|
Sunday, 08/01/2010
|
Novel Phase I Design for Oncology Research
Linda Sun, Merck & Co., Inc.; Keaven M. Anderson, Merck Research Laboratories; Lisa Lupinacci, Merck & Co., Inc.; Yevgen Tymofyeyev, Merck & Co., Inc.
2:05 PM
|
Large-Scale Simulation Evaluation for Model Selection: Lasso and Bayesian Derivatives
Alan Burton Lenarcic, Harvard University; Edoardo M. Airoldi, Harvard University; Palak Patel, Harvard University
2:20 PM
|
Better Learning About the MTD in Phase I Oncology Trial: A Case Study Implementing Bayesian Design Based on Continuous Reassessment Method
Inna Perevozskaya, Pfizer Inc.
2:25 PM
|
Modeling Dependence in Reverse Phase Protein Arrays
Donatello Telesca, University of California, Los Angeles; Peter Muller, MD Anderson Cancer Center; Yuan Ji, MD Anderson Cancer Center
2:25 PM
|
Evaluation of Dose-Finding Designs: On the Interplay Between Theory and Simulation
Assaf P. Oron, University of Washington; Peter Hoff, University of Washington
3:05 PM
|
Statistical Analysis of General Chaotic Networks
Morris Herbert Morgan, III, Hampton University; Carolyn Morgan, Hampton University
3:20 PM
|
Phase I Studies: Goals, Patient Selection, and Implications for Design
Paul H. Frankel, City of Hope; Stephen Shibata, City of Hope; Susan Groshen, University of Southern California, Norris; Jeffrey Longmate, City of Hope; Stella Khoo, City of Hope; Edward Newman, City of Hope
4:05 PM
|
An Evaluation of a Simon 2-Stage Phase II Clinical Trial Design Incorporating Continuous Toxicity Monitoring
Herman Ray, University of Louisville; Shesh Rai, University of Louisville
4:20 PM
|
Revisiting Marginal Regression
Jiashun Jin, Carnegie Mellon University; Christopher Genovese, Carnegie Mellon University; Larry Wasserman, Carnegie Mellon University
4:35 PM
|
Exact Two-Stage Designs for Phase II Clinical Trials with Rank-Based Endpoints
Gregory E. Wilding, State University of New York at Buffalo; Guogen Shan, State University of New York at Buffalo; Alan Hutson, State University of New York at Buffalo
4:35 PM
|
|
Monday, 08/02/2010
|
Implementation of EWOC (Escalation With Overdose Controls) Adaptive Dose-Finding Design in a Phase IIA Clinical Trial
Catherine Bresee, Oschin Comprehensive Cancer Institute; Amir Steinberg, Oschin Comprehensive Cancer Institute; Jeremy Rudnick, Oschin Comprehensive Cancer Institute; Andre Rogatko, Oschin Comprehensive Cancer Institute
|
Comparisons of Methods in Phase I Dose-Escalation Clinical Trial Designs
Liping Huang, Bayer HealthCare Pharmaceuticals
|
A General Framework of Adaptive Designs for Early-Phase Oncology Clinical Trials
Lixin Lang, Bristol-Myers Squibb; Ralph Raymond, Bristol-Myers Squibb
|
Estimating the Agreement and Diagnostic Accuracy of Two Diagnostic Tests When One Test Is Conducted on Only a Subsample of Specimens
Hormuzd A. Katki, National Cancer Institute; Yan Li, The University of Texas at Arlington; Philip E. Castle, National Cancer Institute
8:35 AM
|
Futility Assessment Utilizing Conditional Power in a Phase III Clinical Trial
Yan Sun, Amgen Inc.
8:35 AM
|
A Conditional Bayesian Logistic Regression Model (BLRM) with Overdose Control
Lu-May Chiang, Novartis Pharmaceuticals Corporation; Adarsh Joshi, Eli Lilly and Company; David Ohlssen, Novartis Pharmaceuticals Corporation; Jyotirmoy Dey, Novartis Pharmaceuticals Corporation
9:05 AM
|
Adaptive Factorial Designs for Combination Therapy in Oncology
Donald Arthur Berry, MD Anderson Cancer Center
9:15 AM
|
Variability Exploration in Six Phase III Diabetes Clinical Trials: Implications for Research Studies
Hua Guo, Merck Research Laboratories; Bret Musser, Merck Research Laboratories
9:20 AM
|
EWOC Online: A Novel Web Application for Computing a Bayesian Phase I Design Method for Dose-Finding with Escalation with Overdose Control
Dror Berel, Cedars-Sinai Medical Center; Andre Rogatko, Oschin Comprehensive Cancer Institute
9:35 AM
|
Optimal Two-Stage Phase II Design Utilizing Partial Information for Long-Term Endpoints
Bo Huang, Pfizer Inc.; Enayet Talukder, Pfizer Inc.; Neal Thomas, Pfizer Inc.
9:35 AM
|
Two-Stage Designs with Additional Futility Tests for Phase II Clinical Trials with Heterogeneous Patient Populations
Myron N. Chang, University of Florida; Sin-Ho Jung, Duke University
10:05 AM
|
Examining the Challenges of Missing Data Analysis in Phase Three of the Agricultural Resource Management Survey
Darcy Miller, National Agricultural Statistics Service
2:05 PM
|
Applications of 'Learn' Phase Adaptive Designs
Jose Carlos Pinheiro, Johnson & Johnson; Chyi-Hung Hsu, Novartis Pharmaceuticals Corporation
2:05 PM
|
Evaluation of Design Parameters for an Adaptive Seamless Phase 2b/3 Trial
Susan Y. Zhou, CDER/FDA; Greg Soon, CDER/FDA; Xiao Ding, CDER/FDA; JungYeon Park, CDER/FDA; EunYoung Kim, CDER/FDA; Sue-Jane Wang, FDA
3:05 PM
|
|
Tuesday, 08/03/2010
|
Blood Transfusion After Lung Transplant Using Two-Step Nonlinear Multiphase Generalized Mixed Models
Jeevanantham Rajeswaran, Cleveland Clinic; Eugene H. Blackstone, Cleveland Clinic
|
Using Historical Data for a Transitional Decision of Single-Arm Phase II Clinical Trials
Zunqiu Chen, Oregon Health & Science University; Yiyi Chen, Oregon Health & Science University; Motomi Mori, Oregon Health & Science University
|
Doubly robust inference with missing data in survey sampling
Jae-Kwang Kim, Iowa State University; David Haziza, Université de Montréal
9:00 AM
|
A Graphical Approach to Multiple Test Procedures for Adaptive Phase II/III Clinical Trials
Martin Posch, Medical University of Vienna
9:25 AM
|
Address-Based Area Sampling: An Efficient Hybrid Between Address-Based Sampling and Area Sampling
Avinash C. Singh, NORC; Peter K. Kwok, NORC
10:35 AM
|
Survey Measurement of Complex Latent Constructs: An Example from the National Long Term Care Survey (NLTCS)
Elena A. Erosheva, University of Washington
10:35 AM
|
Multiple Imputation of Disease Status Based on a Two-Phase Sample Design
Steven G. Heeringa, University of Michigan
11:15 AM
|
Hospital Length-of-Stay Modeling by Coxian Phase-Type Regression with Heterogeneity
Xiaoqin Tang, Michigan State University; Zhehui Luo, Michigan State University; Joseph Gardiner, Michigan State University
11:20 AM
|
I-SPY2: Identifying Biomarker Signatures for Therapeutic Agents in Neoadjuvant Breast Cancer
Donald Arthur Berry, MD Anderson Cancer Center; Kyle Wathen, MD Anderson Cancer Center; Nebiyou Bekele, MD Anderson Cancer Center; Laura Esserman, University of California, San Francisco
11:35 AM
|
Multistage-mutiphase BIB Designs
Dr. Md. Shamsuddin, King Abdulaziz University; Mian Arif Shams Adnan, Jahangirnagar University
11:50 AM
|
A Hybrid Geometric Select-and-Test Design Based on Treatment Failure Time and Toxicity
Peter F. Thall, MD Anderson Cancer Center
2:05 PM
|
Nonparametric Profile Monitoring by Mixed Effects Modeling
Peihua Qiu, University of Minnesota
2:05 PM
|
Two-Phase Study: Application to Gene-Environmental Interaction
Jaeil Ahn, University of Michigan; Bhramar Mukherjee, University of Michigan
2:05 PM
|
Optimal Phase II Decision Rules in a Seamless PhaseII/III Clinical Trial
Bo Jin, Merck Research Laboratories
2:05 PM
|
Who Needs Bayesian Phase I Trials?
Rick Chappell, University of Wisconsin-Madison
2:30 PM
|
Evaluating Statistical Methods to Establish Clinical Similarity of Two Biologics: A Real-Life Example
Lei Lei, Amgen Inc.
2:45 PM
|
Phase and Coherency in a Neighborhood of Zero Frequency for Bivariate Long Memory Series
Rebecca J. Sela, New York University; Clifford M. Hurvich, New York University
3:05 PM
|
Confidence Intervals for the Selected Treatment Effect in Multistage Adaptive Designs
Ionut Bebu, Georgetown University Medical Center; Vladimir Dragalin, Pfizer Inc.; George Luta, Georgetown University
3:20 PM
|
|
Wednesday, 08/04/2010
|
Asymmetric Moving Averages Minimizing Phase-Shift
Dominique Ladiray, INSEE; Michel Grun-Rehomme, ENSAE
8:35 AM
|
Efficient Early Phase Designs in Oncology Based on Evidence Synthesis
Jyotirmoy Dey, Novartis Pharmaceuticals Corporation; Wentao Feng, Novartis Pharmaceuticals Corporation
8:35 AM
|
A Nonparametric Change Point Model for Multivariate Phase II Statistical Process Control
Mark David Holland, University of Minnesota; Douglas Hawkins, University of Minnesota
8:35 AM
|
On the Use of Historical Information in Selecting Design Type for Phase II Oncology Trials
Yiyi Chen, Oregon Health & Science University; Rongwei (Rochelle) Fu, Oregon Health & Science University; Zunqiu Chen, Oregon Health & Science University
8:35 AM
|
Phase I Dose-Finding in Cancer Trials Based on a Discrete Time Multistate Model
Lin Yang, MD Anderson Cancer Center; Nebiyou Bekele, MD Anderson Cancer Center; Donald Arthur Berry, MD Anderson Cancer Center
8:50 AM
|
Probability-Proportional-to-Size Sampling from a Rare Population
Jens Olofsson, Örebro University
8:50 AM
|
Noise Assumptions in Complex-Valued SENSE MR Image Reconstruction
Daniel B. Rowe, Marquette University; Iain P. Bruce, Marquette University
9:05 AM
|
Bayesian Adaptive Phase II/III Clinical Trial Design Using the Relationship Between Tumor Response and Survival
Donald Arthur Berry, MD Anderson Cancer Center; Haiying Pang, MD Anderson Cancer Center
9:20 AM
|
Bayesian Design for Nonrandomized Phase II Oncology Trials
Yanmei Xu, GlaxoSmithKline; Bingming Yi, GlaxoSmithKline
10:55 AM
|
Components and Applications of the Three Phases of Census Capture
Douglas Olson, U.S. Census Bureau
11:35 AM
|
Dose-Escalation Approaches for Two Agents in Early-Phase Oncology Studies
Yevgen Tymofyeyev, Merck & Co., Inc.; Christine K. Gause, Merck Research Laboratories; Keaven M. Anderson, Merck Research Laboratories
11:50 AM
|
Simulation of a Phase III Trial Using Realizations of Posterior Distribution Based on a Phase IIb Trial
A. Lawrence Gould, Merck Research Laboratories
2:05 PM
|
Sequential Design of Phase II--III Cancer Trials
Tze Leung Lai, Stanford University; Philip Lavori, Stanford University; Mei-Chiung Shih, Stanford University
2:05 PM
|
Maximizing Response for Households with Children in a Two-Phase Address-Based Sample
Jill Montaquila, Westat; J. Michael Brick, Westat; Douglas Williams, Westat
2:05 PM
|
Probabilistic Approach to Editing
Maiki Ilves, Örebro University
2:20 PM
|
Findings from a Two-Phase Mail Survey for a Study of Veterans
David Cantor, Westat; Richard Sigman, Westat; Daifeng Han, Westat; Maribel Aponte, Veterans Administration
2:25 PM
|
The Role of Bayesian Statistics in Confirmatory Drug Development Trials
David Ohlssen, Novartis Pharmaceuticals Corporation
2:30 PM
|
Strategies for Setting Up the Logistics in Early Phase Adaptive Design Clinical Trials
Eva R. Miller, ICON Clinical Research
3:05 PM
|
An Examination of the Bias Effects with a Two-Phase Address-Based Sample
Daifeng Han, Westat; Jill Montaquila, Westat; Douglas Williams, Westat; J. Michael Brick, Westat
3:05 PM
|
Statistical Methods for a Phase II Oncology Trial with a GMI Endpoint
Stephanie Ann Kovalchik, University of California, Los Angeles; William Leonard Mietlowski, Novartis Oncology
3:20 PM
|
|
Thursday, 08/05/2010
|
Calibration in the Continual Reassessment Method for Phase I Clinical Trials
Shing M. Lee, Columbia University; Ying Kuen Cheung, Columbia University
8:50 AM
|
Sample Correlations of Current Population Survey Unemployment Statistics
Reid Rottach, U.S. Census Bureau
8:55 AM
|
Impact of Missing Data on the Analysis of Crossover Data
Anjela Tzontcheva, Merck & Co., Inc.; Mahtab Marker, Merck & Co., Inc.
9:05 AM
|
Current Population Survey Correlations Across and Within the 1990/2000 Phase-In/Phase-Out Period
Antoinette Lubich, U.S. Census Bureau; Reid Rottach, U.S. Census Bureau
9:15 AM
|
Issues to Consider in Selecting a Response-Adaptive Design for Dose-Finding Experiments
Nancy Flournoy, University of Missouri
9:25 AM
|
Design and Trial Operational Considerations for a Phase II Two-Stage Adaptive Trial
Weili He, Merck & Co., Inc.; Madhuja Mallick, Merck & Co., Inc.; Yevgen Tymofyeyev, Merck & Co., Inc.; James A. Bolognese, Cytel Inc.
10:55 AM
|
|